Advent Life Sciences founds and invests in early- and mid-stage life sciences companies that have a first- or best-in-class approach to unmet medical needs.
Portfolio
2
companies
Cyted Health
Cyted Health develops gastrointestinal molecular diagnostics for early esophageal disease detection.
Proximie
Proximie provides a digital health platform connecting operating rooms globally.
Shahzad Malik
General Partner
Kaasim Mahmood
General Partner
The financing round was led by EQT Life Sciences alongside co-leads Advent Life Sciences and British Business Bank.
"This Series B financing marks a defining moment for Cyted as we continue to deepen our commitment to detecting esophageal diseases earlier. This investment will help us consolidate our leading position in the market by expanding our US presence and adding new life-saving innovations to our advanced diagnostics portfolio."
The Series C financing was led by Advent Life Sciences with backing from several new and existing institutional investors to accelerate product development and scale operations.
"We are delighted to partner with Proximie and a world class group of investors as the company expands its global footprint and product capabilities. The company is a perfect fit for our ethos of backing best-in-class innovative life sciences businesses that have the capability to positively impact human health and healthcare delivery in paradigm changing ways."
.png)